249 related articles for article (PubMed ID: 29636106)
1. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
[TBL] [Abstract][Full Text] [Related]
2. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
[TBL] [Abstract][Full Text] [Related]
3. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa.
Shearer K; Evans D; Moyo F; Rohr JK; Berhanu R; Van Den Berg L; Long L; Sanne I; Fox MP
Trop Med Int Health; 2017 Feb; 22(2):221-231. PubMed ID: 27797443
[TBL] [Abstract][Full Text] [Related]
5. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.
Onoya D; Nattey C; Budgell E; van den Berg L; Maskew M; Evans D; Hirasen K; Long LC; Fox MP
AIDS Patient Care STDS; 2017 May; 31(5):205-212. PubMed ID: 28445088
[TBL] [Abstract][Full Text] [Related]
7. Outcomes after virologic failure of first-line ART in South Africa.
Murphy RA; Sunpath H; Lu Z; Chelin N; Losina E; Gordon M; Ross D; Ewusi AD; Matthews LT; Kuritzkes DR; Marconi VC;
AIDS; 2010 Apr; 24(7):1007-12. PubMed ID: 20397305
[TBL] [Abstract][Full Text] [Related]
8. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
[TBL] [Abstract][Full Text] [Related]
9. Social and behavioral factors associated with failing second-line ART - results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa.
Evans D; Dahlberg S; Berhanu R; Sineke T; Govathson C; Jonker I; Lönnermark E; Fox MP
AIDS Care; 2018 Jul; 30(7):863-870. PubMed ID: 29463102
[TBL] [Abstract][Full Text] [Related]
10. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
[TBL] [Abstract][Full Text] [Related]
11. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
[TBL] [Abstract][Full Text] [Related]
12. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
13. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
[TBL] [Abstract][Full Text] [Related]
14. Second-line antiretroviral therapy: long-term outcomes in South Africa.
Murphy RA; Sunpath H; Castilla C; Ebrahim S; Court R; Nguyen H; Kuritzkes D; Marconi VC; Nachega JB
J Acquir Immune Defic Syndr; 2012 Oct; 61(2):158-163. PubMed ID: 22692090
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
[TBL] [Abstract][Full Text] [Related]
16. Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
Davies MA; Moultrie H; Eley B; Rabie H; Van Cutsem G; Giddy J; Wood R; Technau K; Keiser O; Egger M; Boulle A;
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):270-8. PubMed ID: 21107266
[TBL] [Abstract][Full Text] [Related]
17. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
Eholie SP; Moh R; Benalycherif A; Gabillard D; Ello F; Messou E; Zoungrana J; Diallo I; Diallo M; Bado G; Cisse M; Maiga AI; Anzian A; Toni TD; Congo-Ouedraogo M; Toure-Kane C; Seydi M; Minta DK; Sawadogo A; Sangaré L; Drabo J; Karcher S; Le Carrou J; de Monteynard LA; Peytavin G; Gabassi A; Girard PM; Chaix ML; Anglaret X; Landman R;
Lancet HIV; 2019 Nov; 6(11):e750-e759. PubMed ID: 31601544
[TBL] [Abstract][Full Text] [Related]
18. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
19. It is time to consider third-line options in antiretroviral-experienced paediatric patients?
Zyl GU; Rabie H; Nuttall JJ; Cotton MF
J Int AIDS Soc; 2011 Nov; 14():55. PubMed ID: 22085598
[TBL] [Abstract][Full Text] [Related]
20. Pediatric response to second-line antiretroviral therapy in South Africa.
Zanoni BC; Sunpath H; Feeney ME
PLoS One; 2012; 7(11):e49591. PubMed ID: 23185373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
